Compare PSO & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSO | CYTK |
|---|---|---|
| Founded | 1844 | 1997 |
| Country | United Kingdom | United States |
| Employees | 17116 | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | PSO | CYTK |
|---|---|---|
| Price | $13.05 | $59.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | N/A | ★ $87.56 |
| AVG Volume (30 Days) | 994.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $5.90 | $9.79 |
| Revenue Next Year | $4.88 | $302.66 |
| P/E Ratio | $14.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.02 | $29.31 |
| 52 Week High | $16.70 | $70.98 |
| Indicator | PSO | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 40.30 |
| Support Level | $12.92 | $59.25 |
| Resistance Level | $13.34 | $65.93 |
| Average True Range (ATR) | 0.23 | 2.65 |
| MACD | 0.06 | -0.32 |
| Stochastic Oscillator | 68.24 | 3.98 |
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.